Neurocrine Biosciences Inc. (NBIX) Stock Research, Analysis & News

Quick Analysis on Neurocrine Biosciences Inc. (NBIX) Stock as of March 29, 2020

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Neurocrine Biosciences Inc. (NBIX) Stock below)

Neurocrine Biosciences Inc. (NBIX) Stock Profile Summary

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine-related diseases and disorders. Its products in clinical development include Elagolix, a phase II product for endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for cardiovascular diseases; CRF1 Antagonist, a phase I product for treating mood disorders and irritable bowel syndrome; Vesicular Monoamine Transporter 2 Inhibitor, a phase I product for movement disorders and schizophrenia; and Elagolix, a phase I product for uterine fibroids, and mens and womens health. The companys research programs comprise Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic Drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. Its product pipeline also includes Indiplon 5mg and 10mg capsules, the FDA deemed approvable products, for the treatment of insomnia. The company has collaborations with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize Indiplon in Japan; Abbott Laboratories to develop and commercialize elagolix for the treatment of endometriosis-related pain; and Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Inc. (NBIX) Stock Key Statistics Research and Analysis as of March 29, 2020

Neurocrine Biosciences Inc. (NBIX) Stock Competitor Research and Analysis

Abbott Laboratories (ABT)Eli Lilly & Co. (LLY)
Pfizer Inc. (PFE)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)

Mutual Funds with Neurocrine Biosciences Inc. (NBIX) Stock in its top 10 holdings

FundCategoryNBIX Holding Percentage
Vanguard Market Neutral InvMarket Neutral21.89%

ETFs with Neurocrine Biosciences Inc. (NBIX) Stock in its top 10 holdings

Stock Research on Neurocrine Biosciences Inc. (NBIX)

Latest Market News on Neurocrine Biosciences Inc. (NBIX)


Click here to find the latest news on Neurocrine Biosciences Inc. (NBIX)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Abbott Laboratories (ABT)
Eli Lilly & Co. (LLY)
Pfizer Inc. (PFE)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)